Cocaine Use Disorders Clinical Trial
— SDCNo medications are currently available for treatment of psychostimulant addiction, a compulsive preoccupation with use of cocaine and related compounds. Donepezil is a medication that is currently prescribed for Alzheimer's disease, and selegiline is a medication used for treatment of Parkinson's Disease. Both of these medications can decrease the amount of cocaine injections that laboratory animals choose to inject by vein. This project will determine if combined treatment with donepezil and selegiline can also decrease cocaine-motivated behavior for human subjects in a laboratory setting.
Status | Completed |
Enrollment | 12 |
Est. completion date | May 2013 |
Est. primary completion date | May 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 21 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Meets DSM-IV-TR criteria for cocaine abuse or dependence - At least one cocaine-positive urine within 6 weeks prior to enrollment - Has used cocaine for a duration of at least 6 months - At least weekly cocaine use during the last 30 days Exclusion Criteria: - History of a medical adverse reaction to cocaine or other psychostimulants - Any current Axis I psychiatric disorder other than drug abuse or dependence - Dependence on abused substances other than cocaine - Current or past history of seizure disorder - Heart or lung disease |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Kansas City VA Medical Center | Kansas City | Missouri |
Lead Sponsor | Collaborator |
---|---|
Midwest Biomedical Research Foundation | National Institute on Drug Abuse (NIDA) |
United States,
Grasing K, Mathur D, Newton TF, DeSouza C. Donepezil treatment and the subjective effects of intravenous cocaine in dependent individuals. Drug Alcohol Depend. 2010 Feb 1;107(1):69-75. doi: 10.1016/j.drugalcdep.2009.09.010. — View Citation
Grasing K, Yang Y, He S. Reversible and persistent decreases in cocaine self-administration after cholinesterase inhibition: different effects of donepezil and rivastigmine. Behav Pharmacol. 2011 Feb;22(1):58-70. doi: 10.1097/FBP.0b013e3283428cd8. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in cocaine-reinforced behavior | Participants will make a series of choices between vouchers with an ascending monetary value and intravenous injections of cocaine | days 2 and 24 of dosing | No |
Secondary | How well the study medications are tolerated | Laboratory and self-reported adverse events | 33 days of dosing | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01639157 -
Impact of Buspirone Maintenance on the Reinforcing Effects of Cocaine
|
N/A | |
Completed |
NCT00759473 -
D-Cycloserine Facilitation of Cocaine - Cue Extinction
|
Phase 2 | |
Completed |
NCT00780442 -
D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals
|
Phase 2 | |
Completed |
NCT00178776 -
A Transtheoretical Model Group Therapy for Cocaine
|
Phase 1 | |
Recruiting |
NCT02680288 -
Lorcaserin Intra Venous Cocaine Effects
|
Phase 1/Phase 2 | |
Completed |
NCT02909101 -
Project IMPACT: Improving Memory Performance by Applying Cognitive Training
|
N/A | |
Completed |
NCT01739192 -
A Novel Anti-Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence
|
Early Phase 1 | |
Completed |
NCT02373124 -
Glutamatergic Modulation of Motivation Enhancement: A Pilot Feasibility Trial
|
Phase 1/Phase 2 |